News
13.07.2021

Cromos Pharma highlights Sarcoma Awareness Month

This July, Cromos Pharma is highlighting Sarcoma Awareness Month.

What are sarcomas?

Sarcomas are rare malignant (cancer) tumors that start in the bones and soft tissues. The most common type of sarcoma is soft tissue sarcoma. Four out of five sarcomas occur in soft issues. Over half of these are found in the leg but sarcomas can occur in any part of the body.  

Sarcoma incidence in US and EU

According to the National Cancer Institute, about 12,000 new cases of soft tissue sarcoma and 3,000 bone sarcomas are diagnosed annually in the US[i]It is estimated that approximately 28,000 new cases of sarcoma are diagnosed per year in the EU, of which 84% are soft tissue sarcomas and 14% are bone sarcomas[ii].

Bone sarcomas occur more frequently in children while soft tissue ones are more commonly found in the adult population. Sarcoma’s represent 10 -12% of all cancers in children and teens[iii].

Symptoms

Soft tissue sarcomas may present as a lump often as big as a golf ball deep in the body tissues, under the skin. Bone sarcomas are characterized by pain around the bone and/or a lump growing in size. Symptoms of sarcomas vary a lot from person to person but it is important that you get any unusual lumps checked out by your doctor.

 Treatment

As with all cancers, the earlier a sarcoma is identified and diagnosed the greater the chances of successful treatment will be. Treatment for sarcomas usually involves surgery combined with radiotherapy and/or chemotherapy. Because sarcomas are so diverse there is no “one size fits all” treatment.  

Advances in sarcoma treatment

Recent advances in sarcoma treatment involve an individualized approach. Checkpoint inhibitors have shown promise in treating aggressive sarcomas. Current clinical research is also focusing on immunotherapies for the treatment of “cold” sarcomas. Targeted therapies are also proving to be successful in clinical trials including a recent one at Sloan Kettering in the US evaluating the effectiveness of the drug ivosidenib in treating IDH1-mutant chondrosarcoma, a type of bone cancer[1]. 

Cromos Pharma supporting sarcoma clinical trials

Sarcomas are defined as rare cancers with many subtypes being highly complex. This poses challenges for clinical research in terms of patient recruitment and study design. Cromos Pharma has over a decade of experience in managing clinical trials for sarcoma involving novel and complex study design.  

Contact bd@cromospharma.com to discuss how we can support your next clinical project.

 About Cromos Pharma 

Cromos Pharma is a US-based international contract research organization with 16 years' experience in delivering fully integrated clinical research solutions in all aspects of clinical trials in all clinical phases across a wide range of therapeutic areas. Our expert team boasts wide-ranging expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management. From bioequivalence studies, biosimilars and generics to successfully managing oncology, neurology, dermatology clinical trials our team provides full service solutions to international pharma and biotech in high recruiting regions with high quality data assured.

 Established in 2004, Cromos Pharma has strong regional experience in Central and Eastern Europe supported by an extensive network of offices. Its international HQ is in Portland, Oregon, USA. 

 Sources:


[i] https://www.hopkinsmedicine.org/health/conditions-and-diseases/sarcoma


[ii] https://www.sciencedirect.com/science/article/abs/pii/S0959804912007253


[iii] https://www.sarcoma-patients.eu/en/sarcoma-infographics



Other News:
news

JP Morgan Healthcare Conference: Virtual Booth and Daily Presentations

We have been meeting you at the JP Morgan Healthcare Conference for the past 11 years and there is no way we are going to break with this tradition. Meet us at the CROMOS PHARMA VIRTUAL BOOTH January 11th through 14th from 8 am to 5 pm(PST). Learn about some of the most vital issues in clinical research by attending our daily presentations or stop by anytime for a chat.


01.01.2021
news

Seasons Greetings from Cromos Pharma

Seasons Greetings from everyone at Cromos Pharma. Watch our holiday video here>>
22.12.2020
news

Watch: The benefits of Cromos Pharma and Avance Clinical's biotech initiative

In October we launched an exciting collaboration with Avance Clinical to offer biotechs a scalable clinical trials solution. The collaboration allows biotechs to quickly start their pre-IND early phase studies in Australia, then expand to Central/Eastern Europe to access the large patient populations for their Phase 2 and 3 studies. In this new video you can learn more about the benefits of this initiative.


08.12.2020
news

World AIDS Day 2020: Remarkable progress but the fight continues

Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus. 

01.12.2020
news

Thanksgiving Greetings

Thanksgiving Greetings from everyone at Cromos Pharma. Watch our video here.
20.11.2020
news

World Pancreatic Cancer Awareness Day 2020

Thursday 19 November 2020 is World Pancreatic Cancer Awareness Day. Here at Cromos Pharma we are proud to play our part in supporting clinical trials aimed at finding better treatments for pancreatic cancers. 

19.11.2020
news

FDA Offers Guidance to Enhance Diversity in Clinical Trials

The FDA released a statement (9 November 2020) outlining its commitment to promoting greater diversity in medical product development and issuing a new guidance document outlining the agency's thinking on encouraging greater inclusivity “Enhancing the Diversity of Clinical Trial Populations--Eligibility Criteria, Enrollment Practices, and Trial Designs,”
12.11.2020
news

Cromos Pharma and Avance Clinical share details of innovative collaboration at BIO-Europe 2020

Cromos Pharma and Avance Clinical announced details of their innovative collaboration to offer biotechs scalable clinical trial solutions at BIO-Europe 2020.
28.10.2020
news

Orphan Drugs Market to Reach USD 340.84 Billion by 2027

The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a positive impact on the growth of the overall market in the coming years according to a new report from Fortune Business Insights
26.10.2020
news

Cromos Pharma and Avance Clinical launch scalable clinical trial solution for biotech

Cromos Pharma is delighted to announce a new collaboration with Avance Clinical providing a scalable clinical trial solution for biotech.
08.10.2020
news

Video: Cromos Pharma and Avance Clinical Collaboration

Cromos Pharma and Avance Clinical are joining forces to offer a scalable clinical trial solution for biotechs. Watch the video to find out more>>
08.10.2020
news

Alzheimer's Awareness Month: Q&A with Dr Sabina Brennan

September is World Alzheimer’s Month. Alzheimer’s Disease (AD) is the most well-known form of dementia. Dementia is the collective name for progressive brain conditions affecting memory, thinking, behavior and emotions. Dementia affects almost 50 million people worldwide. While aging is a major risk factor for dementia, it also affects people under 65 years. To mark Alzheimer’s Awareness Month (Sept 2020) we sat down with leading psychologist, neuroscientist and best-selling author Dr Sabina Brennan. Dr Brennan is a brain health expert who has advised Irish and UK governments on policies relating to aging and dementia.  She is the Irish national representative on the Medical and Scientific Advisory Panel for Alzheimer’s Disease International.
28.09.2020
news

Watch Webinar: Where in the world should I locate my pivotal clinical trial?

If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking hereThe webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP. 


24.09.2020
news

Watch our video: Navigating an era of uncertainty

We are pleased to share with you our new video Cromos Pharma: Helping to navigate an era of uncertainty.

02.09.2020
news

Webinar: Where in the world should I locate my pivotal clinical trial?

01.09.2020
news

EU cancer estimates for 2020 reveal 2.7 million new cases

The European Joint Research Council released its 2020 burden of cancer estimates on 22 July, 2020. The report revealed The cancer burden is estimated to have risen to 2.7 million new cases (all types, excluding non-melanoma skin cancer) and 1.3 million deaths in 2020. Female breast cancer remains the most commonly diagnosed.
26.07.2020
news

FDA proposes new rule on reporting requirements to support Right to Try

On July 23, the U.S. Food and Drug Administration (FDA) announced a new proposed rule that would require sponsors and manufacturers who provide an ‘‘eligible investigational drug’’ under the Right to Try Act to submit an annual summary of such use to FDA.
26.07.2020
news

European medicines agencies launch public consultation on joint strategy

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have developed a joint strategy for the next five years. It was released for a two-month public consultation period on 6, July, 2020.
14.07.2020
news

Two new reports find impacts of COVID-19 on clinical trials easing slightly

Two new reports released by GlobalData Healthcare and Medidata find evidence of COVID-19 impacts on clinical trials easing slightly. 
13.07.2020
news

Risk Based Monitoring- a data-centric approach to monitoring

In this Insights@CromosPharma article our Chief Operating Officer Stephanie Finnegan explores the role of Risk Based Monitoring (RBM) in clinical trials, how it has been utilized in response to the current coronavirus pandemic, and how the experience may shape the industry's approach to RBM in the future.
30.06.2020
news

Cromos Pharma Recruits over 300 Patients in Under Two Months into a COVID-19 Clinical Trial

Cromos Pharma, an international CRO, is pleased to announce unprecedented recruitment in a phase IIb trial in patients with moderate to severe COVID-19 infection.
18.06.2020
news

Connect with Cromos Pharma at BIO Digital 2020

Cromos Pharma is delighted to be participating in BIO Digital 2020, June 8-12 2020. 
02.06.2020
news

Cromos Pharma celebrates International Clinical Trials Day 2020

Today (20 May, 2020) marks International Clinical Trials Day 2020. Cromos Pharma wishes to express its gratitude to everyone who participates in  and conducts clinical trials that help turn research into reality and make lifesaving and life-changing medical treatments available to patients all over the world.
20.05.2020
news

First patients enrolled in Cromos Pharma managed Covid-19 trial

Cromos Pharma is proud to be part of the global search for effective COVID-19 treatments. Today (24 April, 2020) we are pleased to announce the enrollment of the first patients in clinical trials designed to be find drugs to treat the symptoms of coronavirus.
27.04.2020
news

Cromos Pharma insights on master protocols

Master protocols are disrupting the clinical trial space by offering a more comprehensive and adaptive approach to studying treatments for the most complex of diseases. Cromos Pharma is delighted to share with you a recently published article on the topic by CEO Dr Vlad Bogin.
27.04.2020
news

Cromos Pharma supporting World Immunization Week

Vaccines are some of our most powerful weapons against deadly diseases. Cromos Pharma salutes all those involved in the development, administration and promotion of vaccines all over the world.
23.04.2020
news

Cromos Pharma wishes you a safe and healthy Easter and Passover

At the most difficult time, the entire Cromos Pharma Team wishes all our patients, clients, investigators, site personnel and partners a safe and healthy Easter and Passover.
10.04.2020
news

European Medicines Agency launches new regulatory science strategy

The European Medicines Agency (EMA) recently (31 March 2020) published its Regulatory Science Strategy to 2025. The strategy provides a plan for advancing regulatory science over the next five years, covering both human and veterinary medicines.
08.04.2020
news

Cromos Pharma to run COVID-19 trial

Cromos Pharma is pleased to announce that it has been enlisted to run a clinical trial of a repurposed drug candidate to treat COVID-19.  
01.04.2020
news

Cromos Pharma committed to delivering in the face of COVID-19 challenges

Cromos Pharma has been closely following the COVID-19 outbreak as it continues to spread across the globe.
13.03.2020
news

Cromos Pharma launches new series to explore the latest developments in clinical trials sector

2020 marks the start of a new decade when we can anticipate several trends to take hold in the global clinical research market. What can we expect in terms of the market in terms of growth and trends? Throughout 2020 Cromos Pharma’s team of experts will look at some of the major trends dominating the current market and future influences on clinical research.
09.03.2020
news

Celebrating the Women of Cromos Pharma on IWD 2020

On the occasion of International Women’s Day (8 March 2020) we at Cromos Pharma are celebrating the enormous contribution of our female team members.
08.03.2020
news

Cromos Pharma launches a new office in Warsaw, Poland

Cromos Pharma, an international provider of clinical trial and drug development services, today (04 MARCH 2020) announced the opening of its new office in Warsaw, Poland. The opening of the new office strengthens Cromos Pharma’s position in Poland where it has been operational since 2015.

“The establishment of the Poland office is a major development in line with Cromos Pharma’s continued expansion in European and US operations marking another milestone in the sustained growth of the Company. Poland is a significant clinical trials market that has many advantages making it highly attractive to international sponsors,” said Dr. Vlad Bogin, CEO, Cromos Pharma, “Cromos Pharma looks forward to offering sponsors an extended range of our expert services through its new office to ensure effective and cost-efficient execution of clinical trials”.

With its 40 million people Poland is one of the largest clinical trials markets in Eastern Europe that has a strong track record of over 20 years in delivering high-quality research. It boasts several advantages including a large naïve population and well-developed research infrastructure. Polish patients are positively disposed to taking part in clinical trials as it offers them an opportunity to access innovative treatments otherwise not always available to them. The country has a large network of highly skilled and motivated clinical investigators and medical professionals keen to participate in clinical research. Poland also offers relatively low costs and excellent patient recruitment.

With excellent rates of patient recruitment, high-quality data, highly skilled and committed investigators, and comparatively low costs, Poland is an attractive location for sponsors. Cromos Pharma is ready to help you access these advantages through our excellent knowledge of the regulatory processes and our existing relationships with sites and investigators.

Learn more about conducting clinical trials in Poland with Cromos Pharma here.

To explore these advantages and the services Cromos Pharma can offer you please email bd@cromospharma.com.

About Cromos Pharma

Cromos Pharma is an international Contract Research Organization (CRO) providing tailored and effective clinical trials management to support the development of drugs that transform healthcare. It offers fully integrated services with expertise in all aspects of clinical trials of all phases in a wide range of therapeutic indications. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has an extensive network of offices across 15 countries and strong regional experience in Central and Eastern Europe. Its European HQ is situated in Dublin, Ireland and its US base is in Portland, Oregon with an operational base in South Florida.
04.03.2020